Compare iShares International Treasury Bond ETF (IGOV) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Eli Lilly And Co — how do they compare? iShares International Treasury Bond ETF trades at $40.59, while Eli Lilly And Co trades at $1,175.96 (market cap $1.02T). The key difference: Eli Lilly And Co pays a 0.6% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| IGOV | LLY | |
|---|---|---|
52-Week High | $43.09 | $1.24K |
52-Week Low | $40.54 | $625.65 |
Market Cap | — | $1.02T |
Sector | — | Health |
Enterprise Value | — | $1.06T |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $40.58, down 0.47% on the day, with a bearish technical outlook driven by moving averages and ADX signals. The stock lacks key valuation and profitability metrics in the provided data. Recent news highlights significant downside risk from high duration exposure amid global inflationary pressures and rising benchmark rates.
The outlook remains cautious due to macroeconomic headwinds and bond market volatility. Investment opportunities are limited without fundamental data, while risks include amplified capital losses from interest rate sensitivity and geopolitical tensions affecting international treasury bonds.
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
